Ionis Pharmaceuticals Inc

-0.04 (-0.09%)
4:00:00 PM EDT: $44.23 -0.01 (-0.02%)
Products, Regulatory

Ionis Says Provides Update On Development Program Evaluating PCSK9 Antisense Medicine For Treatment Of Hypercholesterolemia

Published: 09/23/2022 06:36 GMT
Ionis Pharmaceuticals Inc (IONS) - Ionis Provides Update on Development Program Evaluating Pcsk9 Antisense Medicine for the Treatment of Hypercholesterolemia.
Ion449 (azd8233) Met Primary Endpoint in Phase 2bsolano Study for Patients With Hypercholesterolemia.
Ion449 Will Not Advance Into Phase 3 Development Based on Pre-specified Criteria.
Ion449 Was Generally Safe and Well Tolerated in This Study.
Astrazeneca is Continuing to Analyze Results From Solano Study to Determine Its Next Steps for Program.
Results Did Not Achieve Pre-specified Efficacy Criteria;astrazeneca Has Decided Not to Advance Ion449 Into Phase 3 Development.